Trial Profile
The effect of Tenecteplase on intravenous thrombus and retinal blood flow in patients with branch retinal vein occlusion (BRVO).
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 23 Apr 2020
Price :
$35
*
At a glance
- Drugs Tenecteplase (Primary)
- Indications Branch retinal vein occlusion
- Focus Therapeutic Use
- Acronyms T-BRVO
- 22 Apr 2020 Status changed from recruiting to discontinued.
- 04 Feb 2020 Planned End Date changed from 1 Mar 2016 to 1 Mar 2021.
- 08 Jun 2016 Status changed from not yet recruiting to recruiting.